The studies address aspects of the regulation of hematopoiesis with specific emphasis on the in vitro assessment of hormonal and cellular interactions. Specific studies are outlined in three general areas: 1. Hormonal and cellular interactions in hematopoietic cell growth. We will study the influence of platelet derived growth factor (PDGF) and growth factors released by marrow stromal cells on erythroid, granulocyte/macrophage, and megakaryocytic colony formation in man. The target cell for these interactions (early or late erythroid progenitor) and potential accessory cells will be defined. Inhibitors of in vitro hematopoieses in chronic renal failure (CRF) will be assessed and correlated with the extent of uremia and anemia in patients with a wide range in renal function. We will also treat some patients with CRF with erythropoietin (Ep)-rich human plasma to quantitatively assess their response. Inhibitors found to be active will be partially isolated and a more detailed study of their effect on hematopoietic cell growth carried out employing human and murine hematopoietic cell lines. 2. Ep purification. Increased amounts of human urinary Ep will be purified, antibodies raised to the amino terminal sequences as well as to purified hormone, and immunoaffinity chromatography performed to increase recoveries of active hormone. mRNA from anemic baboon kidney has been extracted and a cDNA library prepared. Various strategies will be employed to label the purified hormone, prepare a radioimmunoassay, and identify clones of genomic material containing Ep-coding sequences. 3. Clonal disorders of the hematopoietic multipotent stem cell. We will continue to use glucose-6-phosphate dehydrogenase (G6PD) as a marker focusing on patients with essential thrombocytosis and employing the human megakaryocyte colony-forming cell assay as well as an assay for a multipotent progenitor.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK019410-12
Application #
3226369
Study Section
Hematology Subcommittee 2 (HEM)
Project Start
1976-05-01
Project End
1990-04-30
Budget Start
1987-05-01
Budget End
1988-04-30
Support Year
12
Fiscal Year
1987
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
Schools of Medicine
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98195
Guthrie, M; Cardenas, D; Eschbach, J W et al. (1993) Effects of erythropoietin on strength and functional status of patients on hemodialysis. Clin Nephrol 39:97-102
Robertson, H T; Haley, N R; Guthrie, M et al. (1990) Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients. Am J Kidney Dis 15:325-32
Adamson, J W; Eschbach, J W (1990) The use of recombinant human erythropoietin in humans. Ciba Found Symp 148:186-95;discussion 195-200
Buckner, F S; Eschbach, J W; Haley, N R et al. (1990) Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens 3:947-55
Adamson, J W; Eschbach, J W (1990) Treatment of the anemia of chronic renal failure with recombinant human erythropoietin. Annu Rev Med 41:349-60
Adamson, J W; Eschbach, J W (1990) The use of recombinant human erythropoietin (rHuEpo) in humans. Cancer Surv 9:157-67
Broudy, V C; Nakamoto, B; Lin, N et al. (1990) Dynamics of erythropoietin receptor expression on erythropoietin-responsive murine cell lines. Blood 75:1622-6
Eschbach, J W; Haley, N R; Adamson, J W (1990) The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin. Contrib Nephrol 78:24-36;discussion 37
Adamson, J W; Eschbach, J W (1990) The use of recombinant human erythropoietin [rHuEpo] in man. Prog Clin Biol Res 352:505-17
Eschbach, J W; Haley, N R; Adamson, J W (1989) The use of recombinant erythropoietin in the treatment of the anemia of chronic renal failure. Ann N Y Acad Sci 554:225-30

Showing the most recent 10 out of 21 publications